Cell Genesys Inc. of Foster City, Calif., and Bio-TechnologyGeneral Corp. of New York have agreed to collaborate on thedevelopment of T cell transplant products for the treatment ofcytomegalovirus (CMV) infection, Cell Genesys announcedMonday.

The agreement grants Cell Genesys an exclusive worldwidelicense to Bio-Technology General's anti-CMV antibodies. Bio-Technology will receive licensing fees and royalty payments.

Cell Genesys will use components of human monoclonalantibodies developed by Bio-Technology General to createproducts with a high degree of specificity for CMV-infectedcells.

The therapeutic benefit of an anti-CMV T cell transplantproduct has not yet been demonstrated in human clinicaltesting, and Cell Genesys does not expect to begin such trialsbefore 1994.

(c) 1997 American Health Consultants. All rights reserved.

No Comments